In this context, it is also important to emphasize that very recent evidence has demonstrated that high mTOR expression is an independent negative prognosticator of clinical outcome to induction chemotherapy in T-ALL patients [10]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.